
# TISC Mann

Alfred E. Mann
School of Pharmacy and
Pharmaceutical Sciences

# Association Between Initial Z-Drug Prescription Duration and Long-Term Use

Jonathan N. Cloughesy<sup>1,2,</sup> Johanna Thunell<sup>3</sup>; Stephen D. Persell<sup>4,5</sup>, Jeffrey A. Linder<sup>4,5</sup>, Mark D. Sullivan<sup>6</sup>, Xiaofan Liu<sup>1</sup>, Jason N. Doctor<sup>1,2,3</sup>

<sup>1</sup> Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California; <sup>2</sup> Sol Price School of Public Policy, University of Southern California; <sup>3</sup> Schaeffer Center for Health Policy & Economics, University of Southern California; <sup>4</sup> Division of General Internal Medicine, Northwestern University Feinberg School of Medicine; <sup>5</sup> Center for Primary Care Innovation, Northwestern University Feinberg School of Medicine; <sup>6</sup> Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine




#### INTRODUCTION

- Zolpidem, eszopiclone, and zaleplon
   (Z-drugs) are the most prescribed
   medications for insomnia in the United
   States.<sup>1</sup>
- Prescriptions often exceed the guideline-recommended duration of no more than than 5 weeks.<sup>1,2</sup>
- Use is associated with risks including dependence and fractures.<sup>3,4</sup>
- Similar to opioids, initial prescribing patterns may contribute to prolonged use.<sup>5</sup>
- We examined the association between the days' supply of an initial Z-drug prescription and long-term use.


#### **METHODS**

- Retrospective cohort study from January 1, 2007, to February 29, 2024.
- Data from Optum's de-identified Clinformatics® Data Mart Database, which contains administrative health claims for members of large commercial and Medicare Advantage health plans in the United States.
- Sample included adults (N = 126,549)
   who filled a Z-drug prescription, had
   no Z-drug fills for ≥1 year prior to the
   index fill, and remained enrolled for
   ≥8 years after the index fill.
- Outcomes measured if the patient (in each year after the index fill year):
  - 1. Filled a Z-drug
  - 2. Filled ≥180 days' supply
  - 3. Days' supply received
- Regression models estimated the
   association between initial Z-drug
   supply (1-14, 15-24, 25-34, ≥35 days)
   and outcomes in each post-index year.
- The index year was excluded to avoid bias from the initial prescription contributing to the outcome.
- Models controlled for age, sex, race
   and ethnicity, education, income, net
   worth, insurance type, and geographic
   region; a random effect accounted for
   within-patient repeated measures.


# **RESULTS**



# Annual rate of ≥180 days' supply by initial days' supply



# Annual days' supply by initial days' supply



# DISCUSSION

- In this retrospective cohort study across the United States, patients who received a larger initial Z-drug supply were more likely to fill additional prescriptions up to seven years after the index fill year, suggesting that early prescribing decisions are associated with long-term use.
- These patients were also more likely
  to fill ≥180 days' supply and receive a
  larger supply of Z-drugs seven years
  after their initial prescription.
- Limitations include a retrospective design, reliance on claims data that do not capture medication use, potential confounding by insomnia severity, and limited generalizability beyond patients with commercial or Medicare Advantage insurance.
- Future research can investigate causal relationships between initial prescribing and long-term use.
- These findings suggest that clinicians consider limiting initial Z-drug prescriptions.

### REFERENCES

- 1. Moore TJ, Mattison DR. Assessment of Patterns of Potentially Unsafe Use of Zolpidem. *JAMA Intern Med*. 2018;178(9):1275-1277. doi:10.1001/jamainternmed.2018.3031
- 2. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med*. 2016;165(2):125-133. doi:10.7326/M15-2175
- 3. Sparks A, Cohen A, Albright B, et al. Benzodiazepine and Z-Drug Safety Guideline. Kaiser Foundation Health Plan of Washington; 2022.
- 4. Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. *PLOS ONE*. 2017;12(4):e0174730. doi:10.1371/journal.pone.0174730
- 5. Barnett ML, Olenski AR, Jena AB. Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use. *N Engl J Med*. 2017;376(7):663-673. doi:10.1056/NEJMsa1610524
- 6. Montoy JCC, Coralic Z, Herring AA, Clattenburg EJ, Raven MC. Association of Default Electronic Medical Record Settings With Health Care Professional Patterns of Opioid Prescribing in Emergency Departments: A Randomized Quality Improvement Study. *JAMA Intern Med*. 2020;180(4):487-493. doi:10.1001/jamainternmed.2019.6544

# CONTACT

Jon Cloughesy, <a href="mailto:cloughes@usc.edu">cloughes@usc.edu</a>